Title

Glycomics: Immunoglobulin GN-glycosylation associated with mammary gland hyperplasia in women

Document Type

Journal Article

Publication Title

OMICS A Journal of Integrative Biology

ISSN

15362310

Volume

24

Issue

9

First Page

551

Last Page

558

PubMed ID

32833579

Publisher

Mary Ann Liebert

School

School of Medical and Health Sciences

Comments

Meng, Z., Li, C., Ding, G., Cao, W., Xu, X., Heng, Y., ... & Wang, W. (2020). Glycomics: Immunoglobulin GN-Glycosylation Associated with Mammary Gland Hyperplasia in Women. OMICS: A Journal of Integrative Biology, 24(9), 551-558. https://doi.org/10.1089/omi.2020.0091

Abstract

© Copyright 2020, Mary Ann Liebert, Inc., publishers 2020. Mammary gland hyperplasia (MGH) is very common, especially among young and middle-aged women. New diagnostics and biomarkers for MGH are needed for rational clinical management and precision medicine. We report, in this study, new findings using a glycomics approach, with a focus on immunoglobulin G (IgG) N-glycosylation. A cross-sectional study was conducted in a community-based population sample in Beijing, China. A total of 387 participants 40-65 years of age were enrolled in this study, including 194 women with MGH (cases) and 193 women who had no MGH (controls). IgG N-glycans were characterized in the serum by ultra-performance liquid chromatography. The levels of the glycan peaks (GPs) GP2, GP5, GP6, and GP7 were lower in the MGH group compared with the control group, whereas GP14 was significantly higher in the MGH group (p < 0.05). A predictive model using GP5, GP21, and age was established and a receiver operating characteristic curve analysis was performed. The sensitivity and specificity of the model for MGH was 61.3% and 63.2%, respectively, likely owing to receptor mechanisms and/or inflammation regulation. To the best of our knowledge, this is the first study reporting on an association between IgG N-glycosylation and MGH. We suggest person-to-person variations in IgG N-glycans and their combination with multiomics biomarker strategies offer a promising avenue to identify novel diagnostics and individuals at increased risk of MGH.

DOI

10.1089/omi.2020.0091

Share

 
COinS